Key Takeaways
- • CT Healthcare Trust's Net Asset Value per ordinary share declined 3.0% (4.44 pence) from 147.55p on 30 April 2026 to 143.11p on 29 May 2026, underperforming during the May reporting period.
- • The trust beat its benchmark despite the NAV contraction, demonstrating outperformance on a relative basis despite absolute value erosion in the underlying healthcare equity portfolio.
- • CT Healthcare Trust maintains an ongoing charge ratio of 1.03% and operates with a base management fee of 0.95% of net asset value, plus a 15% performance fee structure under Columbia Threadneedle's management.
- • Net assets stood at £134.89 million as of 30 November 2025, with the trust targeting absolute returns through an actively managed global healthcare equities strategy.
- • The trust's 52-week range has been volatile, trading between a high of 156.39p and a low of 115.68p, reflecting broader market headwinds affecting healthcare sector valuations.
Summary
CT Healthcare Trust (LSE: CTHT) reported a 3.0% decline in Net Asset Value per ordinary share during May 2026, with NAV falling from 147.55 pence as of 30 April to 143.11 pence on 29 May, a decrease of 4.44 pence. Despite this contraction, the trust achieved relative outperformance against its benchmark index, positioning it favorably within the comparative healthcare investment landscape.
The trust's performance structure reflects Columbia Threadneedle's active management approach, operating under the Seligman Healthcare Strategy. The fund charges investors an ongoing fee of 1.03% annually, comprising a base management fee of 0.95% of net asset value alongside a 15% performance fee on incremental NAV growth. This fee arrangement aligns manager incentives with investor returns, though it carries a cost burden during periods of absolute NAV decline.
As of 30 November 2025, CT Healthcare Trust's total net assets reached £134.89 million GBP. The trust's investment mandate focuses on capturing opportunities within the global healthcare market through a diversified equity and derivatives exposure strategy. Over a broader time horizon, the trust has delivered positive returns—including reported NAV appreciation of 3.2% over certain periods alongside share price appreciation of 5.3%—though recent month-to-month volatility reflects sector-specific headwinds affecting healthcare equities.
The trust's 52-week trading range has been substantial, with the share price trading between 115.68p (52-week low) and 156.39p (52-week high), underscoring the volatility inherent in concentrated healthcare sector exposure. At current levels around 147.66p estimated NAV, the trust offers a dividend yield of 3.66%, attracting income-focused investors alongside those seeking capital appreciation through healthcare market exposure.
The trust's performance structure reflects Columbia Threadneedle's active management approach, operating under the Seligman Healthcare Strategy. The fund charges investors an ongoing fee of 1.03% annually, comprising a base management fee of 0.95% of net asset value alongside a 15% performance fee on incremental NAV growth. This fee arrangement aligns manager incentives with investor returns, though it carries a cost burden during periods of absolute NAV decline.
As of 30 November 2025, CT Healthcare Trust's total net assets reached £134.89 million GBP. The trust's investment mandate focuses on capturing opportunities within the global healthcare market through a diversified equity and derivatives exposure strategy. Over a broader time horizon, the trust has delivered positive returns—including reported NAV appreciation of 3.2% over certain periods alongside share price appreciation of 5.3%—though recent month-to-month volatility reflects sector-specific headwinds affecting healthcare equities.
The trust's 52-week trading range has been substantial, with the share price trading between 115.68p (52-week low) and 156.39p (52-week high), underscoring the volatility inherent in concentrated healthcare sector exposure. At current levels around 147.66p estimated NAV, the trust offers a dividend yield of 3.66%, attracting income-focused investors alongside those seeking capital appreciation through healthcare market exposure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.